Loading...
•
Mar 31, 2022
Novavax Q1 2022 Earnings Report
Announced first quarter financial results and operational highlights.
Key Takeaways
Novavax reported a successful launch of its protein-based COVID-19 vaccine worldwide, achieving its first profitable quarter with $704 million in revenue.
Expanded worldwide authorizations for COVID-19 primary and booster vaccination in adult population aged 18+.
Progressed COVID-19 vaccine regulatory pathway for children aged 12-17 years.
Advanced COVID-19-Influenza Combination (CIC) vaccine candidate clinical development.
Continued COVID-19 vaccine supply and distribution.
Novavax
Novavax
Forward Guidance
Novavax expects to achieve its full year 2022 total revenue of between $4 and $5 billion.